Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- 1 October 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (10), 1307-1316
- https://doi.org/10.1016/s1470-2045(17)30679-4
Abstract
No abstract availableKeywords
Funding Information
- GlaxoSmithKline
- Novartis Pharmaceuticals Corporation
This publication has 26 references indexed in Scilit:
- Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsJAMA, 2014
- Mapping the molecular determinants of BRAF oncogene dependence in human lung cancerProceedings of the National Academy of Sciences of the United States of America, 2014
- Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non–Small Cell Lung CancerClinical Cancer Research, 2013
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to DasatinibScience Translational Medicine, 2012
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF MutationsJournal of Clinical Oncology, 2011
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFRThe New England Journal of Medicine, 2010
- A Confidence Interval for the Median Survival TimeBiometrics, 1982